Core Insights - Cingulate Inc. has appointed Bryan Downey as Chief Commercial Officer to advance the commercialization of CTx-1301, following FDA acceptance of its New Drug Application (NDA) with a target action date of May 31, 2026 [1][12] - The company has completed a $6 million financing transaction to strengthen its cash position and extend its cash runway into the second quarter of 2026, supporting its commercialization efforts pending FDA approval [2][8] Company Developments - Bryan Downey brings over 25 years of experience in commercial strategy and product launches, having held senior roles at Alfasigma USA, Jubilant Pharma, and Sanofi [3][4] - Cingulate's CTx-1301 is designed to provide rapid onset and all-day ADHD symptom control with a single daily dose, differentiating it from existing medications that often require multiple doses [5][12] - The company has partnered with Indegene to establish the commercial infrastructure and market access strategies necessary for the successful launch of CTx-1301 [5] Financial Overview - The $6 million financing was structured as a non-convertible, unsecured promissory note with a 9% annual interest rate, maturing in 18 months, allowing for monthly redemptions post-PDUFA date [8] - The proceeds from the financing will be utilized for working capital and general corporate purposes [8] Product Information - CTx-1301 utilizes Cingulate's proprietary Precision Timed Release™ (PTR™) platform, enabling three timed releases of medication from a single tablet to maintain focus throughout the day [5][12] - The global ADHD market is valued at over $23 billion annually, indicating significant market potential for Cingulate's innovative product [5]

Core Insights - Cingulate Inc. announced that data from its lead ADHD candidate CTx-1301 has been selected for podium presentation at the AACAP Annual Meeting, indicating significant scientific interest in the product [1][2][3] - CTx-1301 is designed as a once-daily, extended-release formulation aimed at improving treatment for ADHD by addressing limitations of current stimulant therapies [3][5] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) platform [1][6] - The company is headquartered in Kansas City, Kansas, and is advancing a pipeline that includes candidates for ADHD and other neuropsychiatric conditions [6] Product Details - CTx-1301 (dexmethylphenidate HCl) utilizes the PTR™ platform to provide three precisely timed releases of medication throughout the day, aiming for rapid onset and full-day symptom control [5] - The product is currently being evaluated under the FDA's 505(b)(2) pathway for ADHD treatment [5] ADHD Context - ADHD affects an estimated 20 million individuals in the U.S., including around 8 million children and 12 million adults, characterized by inattention, hyperactivity, and impulsivity [4] - Current stimulant medications, while the gold standard, often require multiple daily doses and may not provide consistent coverage throughout the day [4]

Core Insights - Cingulate Inc. announced that the FDA has accepted the New Drug Application (NDA) for CTx-1301, a treatment for ADHD, with a target action date of May 31, 2026 [1][3] - The NDA is being reviewed under the FDA's 505(b)(2) pathway, allowing Cingulate to leverage existing data on dexmethylphenidate while demonstrating novel clinical benefits [2][10] - CTx-1301 has shown significant improvements in ADHD symptoms during Phase 3 trials, indicating its potential to address gaps in current ADHD management [4][6] Regulatory Milestone - The acceptance of the NDA marks a significant regulatory milestone for Cingulate and the CTx-1301 program, validating the completeness of their submission [3][5] - The FDA's review will assess the efficacy, safety, and overall risk-benefit profile of CTx-1301 [7] Clinical Results - Phase 3 trials demonstrated that CTx-1301 provides rapid onset of effect and sustained efficacy throughout the day, addressing issues with current stimulant therapies [4][6] - No serious treatment-emergent adverse events were reported, indicating a favorable safety profile [6] Commercial Strategy - Cingulate is preparing for a timely launch of CTx-1301, having completed process transfer and scale-up production with its manufacturing partner [7] - The company is leveraging an AI-driven omnichannel platform to optimize prescriber reach and patient support, with early research indicating strong formulary receptivity for CTx-1301 [8] Market Context - ADHD affects approximately 20 million individuals in the U.S., with stimulant medications being the gold standard for treatment [9] - Current extended-release formulations often require multiple doses, highlighting the need for a once-daily solution like CTx-1301 [9][10]

Core Insights - Cingulate Inc. announced positive top-line results from the CTx-1301-013 study, confirming that its lead candidate CTx-1301 can be taken with or without food, demonstrating a favorable tolerability profile [1][2][6] - CTx-1301 is designed to be a once-daily stimulant medication for ADHD, providing an entire active day of treatment with eight dose strengths for optimal patient care [3][9] - The study involved 27 healthy adult subjects and assessed the pharmacokinetics of a 50 mg dose of CTx-1301 in both fed and fasted states [4][5] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform [1][11] - The company aims to improve treatment outcomes for patients with conditions requiring frequent dosing regimens, starting with ADHD and potentially expanding to anxiety disorders [11] Product Details - CTx-1301 is a novel, investigational, trimodal, extended-release tablet formulation of dexmethylphenidate, which is FDA-approved for ADHD treatment [1][8] - The unique formulation of CTx-1301 allows for a rapid onset and sustained efficacy throughout the day, addressing the challenge of providing an entire active-day duration of action [9][10] Market Context - ADHD affects over 20 million patients in the U.S., with a significant portion of adults experiencing symptoms that persist from childhood [7] - Current trends indicate that the prevalence of adult ADHD is growing faster than that of children and adolescents combined [7]